一品红(300723.SZ)：子公司获得左卡尼汀口服溶液注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its oral solution of L-carnitine, which is indicated for the treatment of primary systemic carnitine deficiency and related conditions [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for L-carnitine oral solution [1] - The approved indication includes treatment for primary systemic carnitine deficiency, which can manifest as recurrent Reye-like syndrome, hypoketotic hypoglycemia, and/or cardiomyopathy [1] - The product is also indicated for short-term and long-term treatment of secondary carnitine deficiency due to congenital metabolic disorders, with recommended dosages for infants and children [1] Industry Summary - L-carnitine is a naturally occurring substance essential for energy metabolism in mammals, primarily facilitating lipid metabolism [1] - The supplement can alleviate metabolic disorders caused by deficiencies, improving the function of skeletal muscle and cardiac tissues [1]